Researchers have potentially identified a new way to target glioblastoma, a highly aggressive form of brain cancer. This experimental therapy seeks to use a perceived weakness within the disease. Though the treatment is still in preclinical trials, the study has caught attention due to its unique approach to tackling the cancer.
With glioblastoma being one of the deadliest cancers, new treatments are urgently needed. Most patients face a survival period of only 12 to 18 months after diagnosis, with just 5% living beyond five years. The study published in Nature posits that a re-evaluation of glioblastoma’s nature could lead to better treatment strategies.
Traditionally, glioblastoma is viewed as an isolated tumor. However, the study suggests that the tumor operates within a network of surrounding cells, which sustain and propagate the cancer. Shan Grewal, a PhD candidate and co-lead author, explains that treating the cancer necessitates addressing this complex ecosystem.
Our findings suggest glioblastoma therapies should not focus exclusively on the cancer cells or immune cells independently, but must account for this whole ecosystem simultaneously.– Shan Grewal
The team identified a protein, GPNMB, present both on glioblastoma cells and macrophages, immune cells associated with the tumor. Understanding this protein’s dual presence allowed the researchers to develop CAR-T cells that target it. This approach aims to disrupt various elements of the cancer’s ecosystem.
Sheila Singh, a senior author, emphasizes that treating glioblastoma involves attacking both the tumor and its supportive environment. Preclinical tests showcased that this therapy eliminated tumors and sustained disease-free conditions in models based on human patient tumors.
The study illuminated critical aspects of glioblastoma’s biology. Grewal notes the dual role of GPNMB in marking cancer cells and macrophages, which shifted their strategy to target the symbiotic relationship between these elements.
Yet, transferring immunotherapy success from blood cancers to glioblastoma has been challenging. The tumor’s ability to shape its environment poses significant obstacles. Researchers suspect these macrophages contribute to the tumor’s resistance against therapy and immune attacks.
Although promising, the treatment is far from clinical application. Determining patient suitability and ensuring safe and effective delivery are yet to be resolved. Grewal stresses the importance of this discovery as a progression, not a ready solution.
Glioblastoma remains one of the most devastating cancers; patients deserve new options. This is a promising step in the right direction.– Shan Grewal